NAMs and MIDD integration aims to advance human-relevant, simulation-informed drug developmentNew Methods Aim to Improve Safety in Drug Development

This guideline examines the integration of New Approach Methodologies (NAMs) and Model-Informed Drug Development (MIDD) as complementary approaches in drug development. NAMs are described as generating human-relevant experimental and computational evidence, while MIDD provides a quantitative framework to integrate and evaluate that evidence. The authors argue that together these approaches can move NAMs toward more central regulatory evidence and support a more simulation-informed, human-relevant, and risk-based paradigm.

The document does not report a study population, sample size, comparator, or follow-up, and no primary outcome or effect sizes are provided. The main synthesized point is conceptual: NAMs and MIDD are complementary rather than competing, with MIDD serving as the quantitative bridge for NAM-generated data.

Limitations are not reported in the source. The authors explicitly caution that the text does not imply an immediate replacement of animal studies, which is an important framing for clinicians and researchers interpreting the guideline.

Practice relevance centers on regulatory and development strategy rather than direct patient care. The approach aims to shift NAMs toward more central regulatory evidence and to support a more simulation-informed, human-relevant, and risk-based drug development paradigm. No safety data, adverse events, or tolerability information are reported.